Cited by 392CAR-T cell therapy researchMultiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

The DOI matches its Crossref record; 34 of the 35 references it cites were found in a registry or an index.

GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells

Open access

Smith, Eric L., Harrington, Kim, Staehr, Mette, Masakayan, Reed, Jones, Jon, Long, Thomas J., Ng, Khong Y., Ghoddusi, Majid, Purdon, Terence J., Wang, Xiuyan, Do, Trevor, Pham, Minh Thu, Brown, Jessica M., De Larrea, Carlos Fernandez, Olson, Eric, Peguero, Elizabeth, Wang, Pei, Liu, Hong, Xu, Yiyang, Garrett-Thomson, Sarah C., Almo, Steven C., Wendel, Hans-Guido, Riviere, Isabelle, Liu, Cheng, Sather, Blythe, Brentjens, Renier J.·2019·Science Translational Medicine

DOI 10.1126/scitranslmed.aau7746PMC PMC7508042

Open this paper in CoChat — free account

Abstract

GPRC5D is an attractive target for immunotherapy of myeloma, and optimized GPRC5D-targeted CAR T cells eradicate myeloma xenografts.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1126/scitranslmed.aau7746

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Park, J. H., Rivière, I., Gonen, M., Wang, X., Sénéchal, B., Curran, K. J., Sauter, C., Wang, Y., Santomasso, B., Mead, E., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709919 · Cited by 2,688
Self-citation
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Rivière, I., Wang, X., Bartido, S. M., Park, J. H., Curran, K. J., Chung, S. S., Stefanski, J., Bórquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,514
Self-citation
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Kantarjian, H. M., Stein, A. S., Gökbuget, N., Fielding, A. K., Schuh, A. C., Ribera, J., Wei, A. H., Dombret, H., Foà, R., Bassan, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609783 · Cited by 2,204
4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors
Long, A. H., Haso, W. M., Shern, J. F., Wanhainen, K. M., Murgai, M., Ingaramo, M., Smith, J. P., Walker, A. J., Kohler, M. E., Venkateshwara, V. R., et al. (2015) · Nature Medicine · doi:10.1038/nm.3838 · Cited by 1,815
CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy
Fry, T. J., Shah, N. N., Orentas, R. J., Stetler‐Stevenson, M., Yuan, C. M., Ramakrishna, S., Wolters, P. L., Martin, S. C., Delbrook, C., Yates, B., et al. (2017) · Nature Medicine · doi:10.1038/nm.4441 · Cited by 1,363
Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy
Sotillo, E., Barrett, D. M., Black, K. L., Bagashev, A., Oldridge, D. A., Wu, G. S., Sussman, R. T., Lanauze, C. B., Ruella, M., Gazzara, M. R., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1020 · Cited by 1,279
Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8 + and CD4 + CD19-specific chimeric antigen receptor–modified T cells
Turtle, C. J., Hanafi, L.-A., Berger, C., Hudecek, M., Pender, B., Robinson, E., Hawkins, R., Chaney, C., Cherian, S., Chen, X., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf8621 · Cited by 1,016 · cited 14×
“R. Gardner, D. Wu, S. Cherian, M. Fang, L.-A. Hanafi, O. Finney, H. Smithers, M. C. Jensen, S. R. Riddell, D. G. Maloney, C. J. Turtle, Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy.”
Influential
T Cells Genetically Modified to Express an Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma
Brudno, J. N., Marić, I., Hartman, S. D., Rose, J. J., Wang, M., Lam, N., Stetler‐Stevenson, M., Salem, D., Yuan, C. M., Pavletic, S. Z., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.77.8084 · Cited by 792

Show all 35 references

Research works printed but not linked: 1

A. D. Cohen, A. L. Garfall, E. A. Stadtmauer, S. F. Lacey, E. Lancaster, D. T. Vogl, B. M. Weiss, D. E. Ambrose, A. M. Nelson, F. Chen, G. Plesa, I. Kulikovskaya, V. Gonzalez, M. Gupta, R. M. Young, K. Dengel, L. O’keefe, S. Le, C. Richardson, R. E. Isaacs, J. J. Melenhorst, B. L. Levine, C. H. June, M. C. Milone, Safety and efficacy of B-cell maturation antigen (BCMA)-specific chimeric antigen receptor T cells (CART-BCMA) with cyclophosphamide conditioning for refractory multiple myeloma (MM). Blood 130, 505 (2017).

Sorted by citations

Items 301–392 of 392

T cell margination: investigating the detour of T cells following forimtamig treatment in humanized mice
O’Brien, N., Mueller, J., Bröske, A.-M. E., Attig, J., Osl, F., Crisand, C., Wolf, A., Rae, R., Lechner, S., Pöschinger, T., et al. (2024) · mAbs · doi:10.1080/19420862.2024.2440578 · Cited by 2
SOHO State of the Art Updates and Next Questions | Manuscript Title: Bispecific T-Cell Engagers: Sequencing, B-Cell Maturation Antigen, GPRC5D, and Resistance
Ayyappan, S. R., Larsen, J. T., Sanchez, J. F., & Krishnan, A. Y. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.04.006 · Cited by 2
Bispecific T-cell engager therapy for multiple myeloma
Cirstea, D. D., Puliafito, B. R., Kim, B. E., Lei, M., & Raje, N. S. (2025) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2025.101649 · Cited by 2
Discovery of Potential GPRC5D Inhibitors through Virtual Screening and Molecular Dynamics Simulations
Chen, X., Yang, X., Chen, R., Xu, L., Dong, X., & Cai, Z. (2025) · ChemistryOpen · doi:10.1002/open.202500360 · Cited by 2
The role of the bone marrow microenvironment in disease progression and drug resistance in multiple myeloma in the era of novel agents
Guadagno, L., Schütt, J., Brinkert, K., Schenk, T., & Brioli, A. (2025) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2025.2575438 · Cited by 2
Adoptive T‐cell therapies in the clinic
Shaha, S., Lourenco, L., Zhao, Z., & Mitragotri, S. (2025) · Bioengineering & Translational Medicine · doi:10.1002/btm2.70086 · Cited by 2
Immunotherapy in multiple myeloma: advances from immune microenvironment insights to clinical application
Zhang, Y., Lei, Y., Huang, Y., Gao, Y., Liu, R., Guo, K., Zhao, C., & Lei, M. (2025) · Molecular Biology Reports · doi:10.1007/s11033-025-11317-1 · Cited by 2
GPCRs in CAR‐T Cell Immunotherapy: Expanding the Target Landscape and Enhancing Therapeutic Efficacy
Liu, Z., Xiao, Y., Zhao, Y., Dai, L., Shih, D. J. H., Liang, S., Tian, H.-L., Liu, L., Tian, F., Liu, B., et al. (2025) · Advanced Science · doi:10.1002/advs.202517188 · Cited by 2
Determinants of Efficacy and Optimization of Chimeric Antigen Receptor T-Cell Therapy for Treating Multiple Myeloma: Current Status and Future Perspectives
Yasui, H., Doki, N., Yan, W., Imai, K., & Ishida, T. (2026) · Cells · doi:10.3390/cells15040380 · Cited by 2
Translational strategy to support the first-in-human study of a TCR-like T cell bispecific with an in vitro-based safety approach
Augustin, A., Avignon, B., Boetsch, C., Breous-Nystrom, E., Broders, O., Cabon, L., Dernick, K., Durr, E., Eigenmann, M. J., Fischer, S., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1736584 · Cited by 2
Chimeric antigen receptor-T cell therapy-induced cardiotoxicity: Pathophysiological mechanisms and pharmacological intervention strategies
Xu, L., Wu, H., Wu, C., & Xu, Y. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108316 · Cited by 3
Self-citation
Navigating the Therapeutic Landscape of Multiple Myeloma: Immunotherapy, Microenvironment, and Resistance
Mondal, S., Becker, N. J., Huo, Y., Zhang, P., Johnson, T. S., Landgren, O., Coffey, D. G., Walker, B. A., & Liu, E. (2026) · Biomedicines · doi:10.3390/biomedicines14071556 · Cited by 2
Natural Taste Modulators and Microbiome-Aware Nutritional Support for Immunotherapy-Associated Dysgeusia: A Translational Perspective for Precision Supportive Cancer Care
Fleischer, A. (2026) · Nutrients · doi:10.3390/nu18142393 · Cited by 2
From spear to trident: Upgrading arsenal of CAR-T cells in the treatment of multiple myeloma
Zhao, J., Zheng, M., Ma, L., Guan, T., & Su, L. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e29997 · Cited by 2
Emerging Role of Antibody-Drug Conjugates and Bispecific Antibodies for the Treatment of Multiple Myeloma
Tai, W., Wahab, A., Franco, D., Shah, Z., Ashraf, A., Abid, Q., Mohammed, Y. N., Lal, D., & Anwer, F. (2022) · Antibodies · doi:10.3390/antib11020022 · Cited by 2
Current progress of CAR-T-cell therapy for patients with multiple myeloma
Nakashima, T., & Kagoya, Y. (2024) · International Journal of Hematology · doi:10.1007/s12185-024-03794-0 · Cited by 4
Doubling down on GPRC5D in multiple myeloma
Neri, P. E. (2025) · Blood · doi:10.1182/blood.2024027362 · Cited by 2
Emerging therapies in Multiple Myeloma: Leveraging immune checkpoint inhibitors for improved outcomes
Mandavkar, A. A., Padakanti, S. S. N., Gupta, S., Akram, S., Jaffar, N., Chauhan, J., Allu, L. R., Saini, P., Nasrallah, J., Omar, M. A., et al. (2025) · Human Antibodies · doi:10.1177/10932607241301699 · Cited by 2
Chimeric Antigen Receptor T Cell Therapy and Its Significance in Multiple Myeloma
Padda, J., Khalid, K., Zubair, U., Peethala, M. M., Kakani, V., Goriparthi, L., Almanie, A. H., Cooper, A. C., & Jean-Charles, G. (2021) · Cureus · doi:10.7759/cureus.15917 · Cited by 2
Novel Therapies in BCMA-exposed Relapsed/Refractory Multiple Myeloma: The Anti-BCMA Therapy-refractory Patient
Golden, E., Ingram, S., Schade, H. H., Matous, J., & Gregory, T. K. (2022) · touchREVIEWS in Oncology & Haematology · doi:10.17925/ohr.2022.18.1.59 · Cited by 2
Treatment Strategy for Ultra-High-Risk Multiple Myelomas with Chromosomal Aberrations Considering Minimal Residual Disease Status and Bone Marrow Microenvironment
Suzuki, K., & Yano, S. (2023) · Cancers · doi:10.3390/cancers15092418 · Cited by 2
Embracing Myeloma Chimeric Antigen Receptor-T: From Scientific Design to Clinical Impact
Hosoya, H., Rodríguez‐Otero, P., Sidana, S., & Borrello, I. (2023) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_389860 · Cited by 2
Latest Developments in Cellular Therapy for Multiple Myeloma
Gregory, T. K., Schade, H. H., & Berdeja, J. G. (2021) · touchREVIEWS in Oncology & Haematology · doi:10.17925/ohr.2021.16.2.111 · Cited by 2
Technology Spotlight Surface Target Discovery for Blood Cancer Immunotherapies
Patiño-Escobar, B., Lugo, L. M. P., & Wiita, A. P. (2025) · The Hematologist · doi:10.1182/hem.v22.1.2025214 · Cited by 1
CAR-T cell therapy for multiple myeloma: An update on the current state and future potential
Pophali, P. A., Rosenblatt, J. M., & Avigan, D. (2025) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2025.101659 · Cited by 1
How should we choose optimal salvage treatments following BCMA-directed CAR T-cell therapy?
Suresh, A., Pan, D., Lipof, J. J., Kumar, A. D., Arora, S., Sayre, P. H., Wolf, J. L., Martin, T. G., Chari, A., & Chung, A. (2025) · Immunotherapy · doi:10.1080/1750743x.2025.2571392 · Cited by 1
Reversing the sequence: Efficacy of BCMA‐directed therapy following progression on GPRC5D ‐directed therapies in relapsed multiple myeloma
Joiner, L., Giri, S., Ravi, G., Godby, K. N., Hagedorn, C., Costa, L. J., & Bal, S. (2025) · British Journal of Haematology · doi:10.1111/bjh.70176 · Cited by 1
Identification and transformation of novel targets for immunotherapy in multiple myeloma
Wang, Y., Wang, Y., Ma, J., Jing, H., Liu, L., Qiu, L., & Hao, M. (2025) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003869 · Cited by 1
Advances and future perspectives in chimeric antigen receptor T-cell and bispecific antibody therapies for multiple myeloma
Suzuki, T., & Iida, S. (2025) · Journal of Clinical and Experimental Hematopathology · doi:10.3960/jslrt.25038 · Cited by 2
Efficacy and safety of BCMA- or GPRC5D-directed CD3 bispecific antibodies in relapsed/refractory multiple myeloma: a systematic review and meta-analysis of prospective clinical trials and real-world studies
Li, J.-S., Abulaiti, A., Li, D.-Y., Zhao, Y., Wahafu, P., Maimaitiming, M., Qiu, S., Zhang, Y.-X., An, Y.-Q., Wang, W.-X., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1811816 · Cited by 1
Patient‐Specific Determinants of Response to BCMA ‐ and GPRC5D ‐Targeted CAR T‐Cell Therapy in Multiple Myeloma: A QSP Analysis of Clinical Trial and Real‐World Data
Kostiou, V., Chelliah, V., van der Graaf, P. H., Kierzek, A. M., Farzana, T., Mailankody, S., & Jurgens, E. M. (2026) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.70378 · Cited by 1
Toxicities of CAR-T, Bispecific Antibodies, and Antibody–Drug Conjugates in Multiple Myeloma: A Practical Approach to Risk Mitigation and Management
Hej-Ali, S., Banwell, K., Mohamed, H., Cervi, A., Dass, A., Gupta, R., Hamm, C. M., Kanjeekal, S. M., Strange, I. S., Szalay, M., et al. (2026) · Cancers · doi:10.3390/cancers18132083 · Cited by 1
Essentials of CAR-T Therapy and Associated Microbial Challenges in Long Run Immunotherapy
Kalim, M., Jing, R., Li, X., Jiang, Z., Zheng, N., Wang, Z., Wei, G., & Lu, Y. (2024) · Journal of Cellular Immunology · doi:10.33696/immunology.6.189 · Cited by 2
The Evolving Treatment Landscape for the Elderly Multiple Myeloma Patient: From Quad Regimens to T-Cell Engagers and CAR-T
Rees, M. J., & Quach, H. (2025) · Cancers · doi:10.3390/cancers17152579 · Cited by 1
Dermatologic Adverse Events Associated with T-Cell Engager Therapy
Patil, M. K., Wang, B., LeBoeuf, N. R., Nambudiri, V. E., & Shi, C. R. (2026) · American Journal of Clinical Dermatology · doi:10.1007/s40257-026-01041-2 · Cited by 1
Target‐Specific Dermatological Adverse Event Reporting With T‐Cell–Engaging Bispecific Antibodies: A Pharmacovigilance Analysis of FAERS and Canada Vigilance, 2016–2026
Mandal, S., Maji, M., & Dhali, A. (2026) · Cancer Medicine · doi:10.1002/cam4.72241 · Cited by 1
Chimeric Antigen Receptor (CAR) Redirected T Cells
Holzinger, A., & Abken, H. (2020) · Learning materials in biosciences · doi:10.1007/978-3-030-54630-4_10 · Cited by 2
Proceedings from the Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Immune and Cellular Therapy in Multiple Myeloma
Holstein, S. A., Asimakopoulos, F. A., Azab, A. K., Bianchi, G., Bhutani, M., Crews, L. A., Cupedo, T., Giles, H. V., Gooding, S., Hillengaß, J., et al. (2022) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2022.05.019 · Cited by 1
Self-citation
Chimeric Antigen Receptor T Cells in Multiple Myeloma
Shah, P., & Sperling, A. S. (2023) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2023.05.008 · Cited by 1
GPRC5D as a promising therapeutic target in EGFR-wild and immuno-cold non-small cell lung cancer
Mei, J., Cai, Y., Jiang, G., Zhao, H., Wang, R., Song, C., Wan, Y., & Mao, W. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04415-w · Cited by 1
Monumen-TAL progress in the treatment of relapsed multiple myeloma
Bal, S. (2025) · The Lancet Haematology · doi:10.1016/s2352-3026(25)00009-2 · Cited by 1
Strategies for salvage therapy post CAR-T therapy failure in refractory/relapsed multiple myeloma patients
Min, C., Zhong, X., Cui, Y. J., Zhang, H., & Wang, Q. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1515555 · Cited by 1
Therapeutic Advances Propelled by Deciphering Tumor Biology and Immunology—Highlights of the 8th Heidelberg Myeloma Workshop
Lutz, R., Friedrich, M., Raab, M. S., Weinhold, N., & Goldschmidt, H. (2021) · Cancers · doi:10.3390/cancers13164135 · Cited by 1
Fast and furious: Changing gears on the road to cure with chimeric antigen receptor T cells in multiple myeloma
Gagelmann, N., & Merz, M. (2024) · Seminars in Hematology · doi:10.1053/j.seminhematol.2024.07.002 · Cited by 1
Value Passing in Stochastically Timed Process Algebras: A Symbolic Approach based on Lookahead
Bernardo, M. (2000) · Cited by 1
Editorial: Screening and verification of new targets for CAR-T immunotherapy in cancer
Su, Y., Chen, Y., & Shi, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1189773 · Cited by 1
MiniCARbids: Minimalistic human binding domains specifically tailored to CAR T applicationsPreprint
Teufl, M., Mayer, J., Holzer, K. E., Emminger, D., Sylvander, E., Baik, H., Schubert, F., Maniaki, E., Bader, U., Muñoz‐López, Á., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.09.675083 · Cited by 1
Future prospects of chimeric antigen receptor T‐cell therapy for multiple myeloma
de Larrea, C. F., Mailankody, S., Landgren, O., & Smith, E. L. (2019) · Advances in Cell and Gene Therapy · doi:10.1002/acg2.72
Self-citation
Biological and Translational Considerations regarding the Recent Therapeutic Successes and Upcoming Challenges for Multiple MyelomaPreprint
Mitsiades, C. S. (2020) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a034900
Immune Therapies for Hematologic Malignancies
Olnes, M. J. (2021) · Cancers · doi:10.3390/cancers13020295
Bioinformatic gene expression analysis demonstrates a limited number of multiple myeloma specific therapeutic targets
Ramesh, M., Favaloro, J., Bryant, C. E., Ho, P. J., & Abadir, E. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2021.1885660
Chimeric Antigen Receptor–Modified Immune Effector Cell Therapies
Smith, E. L., & Brentjens, R. J. (2021) · The Cancer Journal · doi:10.1097/ppo.0000000000000518
Self-citation
Arrangement of V L and V H Domains in VRC01-Based Chimeric Antigen Receptor (CAR) Affects Functions and Exhaustion Status of CAR-T Cells
Nunoya, J.-I., Teramura, E., Masuda, M., & Su, L. (2021) · Re GEN Open · doi:10.1089/regen.2021.0005
BCMA-Directed CAR T-Cells: Early Results and Future Directions
Berdeja, J. G. (2021) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/s2152-2650(21)01250-7
Myélome multiple et anticorps bispécifiques
Escure, G., & Manier, S. (2021) · Bulletin du Cancer · doi:10.1016/j.bulcan.2021.10.003
Splice Variants of G Protein-Coupled Receptors Expressed in Cancers: Effective Targeting with Monoclonal Antibodies and Antibody-Like Scaffolds As Ligands Irrespective of the Pharmacological Status of Isoforms
Wookey, P. J., Gupta, P., Hare, D. L., Ciccotosto, G. D., & Hutchings, C. J. (2022) · Springer eBooks · doi:10.1007/978-3-030-80962-1_261-1 · Cited by 1
Cellular and Vaccine-Based Immunotherapy for Hematologic Malignancies
Avigan, Z. M., Boussi, L. S., & Avigan, D. (2023) · Interdisciplinary cancer research · doi:10.1007/16833_2023_131
Chimeric Antigen Receptor Therapy in Multiple Myeloma
Ferreri, C., Afrough, A., dillard, C., & Patel, K. K. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-79833-4.00022-x
Clinical Advances in CAR T Cell Therapies for the Patients with Multiple Myeloma
韦, 学. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.1361478
The Future of Chimeric Antigen Receptor T Cell Therapy
Smith, E. L. (2023) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2023.06.005
Self-citation
CAR-T cell therapy for multiple myeloma
Hosen, N. (2023) · Japanese Journal of Transplantation and Cellular Therapy · doi:10.7889/tct-23-023
Design, Synthesis and Anticancer Properties of Novel Hydrazino-Fused Pyrimidines
Mittapalli, S. K., Rizwana, I., Murthy, C. H. P., Jain, N., Pamu, S., & Gupta, P. K. (2023) · Oriental Journal Of Chemistry · doi:10.13005/ojc/390503
The Age of Immune-therapy in Multiple Myeloma with a Collective Goal for a Cure
Larios, J. M., & Terebelo, H. R. (2023) · Medical Research Archives · doi:10.18103/mra.v11i10.4607
The Immune System and Hematopoietic Stem Cells
Elshimali, Y., Chatty, E. M., & Vadgama, J. V. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15717-2.00094-9
Unlocking hope: talquetamab in multiple myeloma treatment: a bispecific breakthrough targeting CD3 and GPRC5D
Amir, S., Laique, F., & Azam, M. M. (2024) · International Journal of Scientific Reports · doi:10.18203/issn.2454-2156.intjscirep20241321
5. Progress in Cellular Immunotherapy for Cancer
Hosen, N. (2023) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.112.1673
CHIMERIC ANTIGEN RECEPTOR T CELLS FOR THE TREATMENT OF MULTIPLE MYELOMA
Testa, U., Pelosi, E., & Castelli, G. (2024) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2024.077
CD34+ and CD34− MM cells show different immune-checkpoint molecule expression profiles: high expression of CD112 and CD137 ligand on CD34+ MM cells
Fukui-Morimoto, A., Serizawa, K., Fujimoto, K., Hanamoto, A., Iwata, Y., Kakutani, H., Kumode, T., Hirase, C., Morita, Y., Tatsumi, Y., et al. (2024) · International Journal of Hematology · doi:10.1007/s12185-024-03867-0
New Insights on Success and Failed Drugs
Sun, Z., & Zhou, Y. (2024) · Springer eBooks · doi:10.1007/978-981-97-7274-2_10
Anticuerpos biespecíficos en el mieloma múltiple en recaída
de Larrea, C. F., Rosiñol, L., Rodríguez-Lobato, L. G., & Tovar, N. (2024) · Revista Sangre · doi:10.24875/sangre.m24000027
Adoptive cellular therapies in multiple myeloma
Kegyes, D., Borlea, B., Damian, M., Țigu, A. B., Nistor, M., Cenariu, D., Munteanu, R. A., Gulei, D., DASCALESCU, A. S., Antohe, I., et al. (2025) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2025.101638
Splice Variants of G Protein-Coupled Receptors Expressed in Cancers: Effective Targeting with Monoclonal Antibodies and Antibody-Like Scaffolds As Ligands Irrespective of the Pharmacological Status of Isoforms
Wookey, P. J., Gupta, P., Hare, D. L., Ciccotosto, G. D., & Hutchings, C. J. (2025) · Springer eBooks · doi:10.1007/978-3-032-00771-1_261
Analysis of a fractional-order cancer model incorporating combined therapeutic approaches
Adejoh, P., Emmanuel, O. N., & Ada, A. E. (2025) · Dutse Journal of Pure and Applied Sciences · doi:10.4314/dujopas.v11i3d.22
Glu(tamine)ing together myeloma metabolism and CAR T efficacy
Wiita, A. P. (2025) · Blood · doi:10.1182/blood.2025031096
Targeting GPRC5D With CAR‐T Cells in Relapse/Refractory Multiple Myeloma: Case Report and Literature Review
Yan, S., Ming, X., Wu, J., Peng, D., Zhou, M., & Xiao, Y. (2025) · Case Reports in Hematology · doi:10.1155/crh/5900306
Additional file 1 of GPRC5D as a promising therapeutic target in EGFR-wild and immuno-cold non-small cell lung cancer
Mei, J., Cai, Y., Jiang, G., He, Z., Wang, R., Song, C., Wan, Y., & Mao, W. (2023) · Figshare · doi:10.6084/m9.figshare.23938549
Additional file 1 of Broadly applicable TCR-based therapy for multiple myeloma targeting the immunoglobulin J chain
Meeuwsen, M. H., Wouters, A. K., Wachsmann, T. L. A., Hagedoorn, R. S., Kester, M. G. D., Remst, D. F. G., van der Steen, D. M., de Ru, A. H., van Hees, E. P., Kremer, M., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26571622
The ancestral haplotype of P2RX5 yields a B-cell surface marker and a multi-lineage immunotherapy targetPreprint
Ang, Z., Castro, A., Paruzzo, L., Schimdt, C., Hasanali, Z. S., Hayer, K. E., Stella, F., Soldan, S. S., Torres-Diz, M., Kwok, C., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.14.698748
Subsequent CAR-T and engineered antibody for relapsed/refractory multiple myeloma following BCMA-targeted treatment: a systematic review and meta-analysis
Kang, Y., Liu, Q., Liu, Q., Xie, W., Sun, C., & Mei, H. (2026) · Blood Cancer Journal · doi:10.21203/rs.3.rs-8750940/v1
One ball, two hits
Lee, H. (2026) · Blood · doi:10.1182/blood.2025031561
Bispecific Antibodies and CAR-T cell Therapy in Multiple Myeloma
Locke, M., Lee, A., & Nieto, M. J. (2026) · Journal of Clinical Haematology · doi:10.33696/haematology.7.074
Clickable Universal Tumor-Antigen Equipping Strategy for Remedial Chimeric Antigen Receptor T Cells to Destroy Solid Tumors
Shabiti, S., Pan, H., Xu, X. X., Xu, S., Xu, Z., Zheng, J., Zhang, X., Li, F., Ke, Y., Wang, Y., et al. (2026) · ACS Nano · doi:10.1021/acsnano.6c00238
Efficacy and safety of CD38-directed CAR-T cell therapy for multiple myeloma: a systematic review and meta-analysis
Xu, X., Dong, C., Guo, J., Chang, X., Zhang, Y., Gou, S., Xue, L., & Li, J. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1744250
Patient‐Centric First‐in‐Human Dose Selection: An Ex Vivo Minimal Anticipated Biological Effect Level Approach for T‐Cell Engagers in Multiple Myeloma
Kraft, T. E., Marrer‐Berger, E., Belli, S., Haegel, H., Schneider, A., Giusti, A. M., Bscheider, M., Jacob, W., Weisser, M., Blanco, L., et al. (2026) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.70366
Bone Marrow Homing and GPRC5D‐Targeting Engineered Cell Membrane‐Camouflaged Hypoxia‐Responsive Nanoparticles for Multiple Myeloma Therapy
Chu, B., Li, S., Wei, X., Wu, X., Yang, P., Chen, M., Zhang, F. C., Wang, F., Huang, J., Zhai, X., et al. (2026) · Advanced Functional Materials · doi:10.1002/adfm.202532144
Molecular targets in blood cancer
Maity, P., & Haloi, P. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-43846-2.00012-x
Infection risk associated with talquetamab in relapsed/refractory multiple myeloma: a systematic review with meta-analysis of talquetamab monotherapy and descriptive analysis of combination therapy
Huang, Z.-Y., Wu, W., Luo, G., Huang, H., & Liu, X.-L. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1848518
Clinical features and management of GPRC5D-associated adverse events in novel GPRC5D × CD3 bispecific talquetamab-treated relapsed/refractory multiple myeloma patients: the MonumenTAL-1 China cohort experience
An, G., Jin, J., Cai, Z., Jing, H., Fu, C., He, P., Xia, Z., Xu, Q., Liu, R., Li, L., et al. (2026) · Hematology · doi:10.1080/16078454.2026.2702681
Bridging Innovation in Multiple Myeloma Care: A Review of Novel Therapies
Michelly De Castro, D., & Ow, K. (2026) · Journal of the Advanced Practitioner in Oncology · doi:10.6004/jadpro.2026.17.7.25
CAR-T Cell Therapy: Engineering Remission in Refractory Myeloma
Sperling, A. S. (2026) · The Cancer Journal · doi:10.1097/ppo.0000000000000854
Dual targeting of BCMA and GPRC5D with the trispecific antibody ramantamig addresses antigenic heterogeneity in myeloma
O’Neill, C. A., Broekmans, M. E. C., Korst, C. L. B. M., Krevvata, M., Collo, G. D., Groen, R. W. J., Li, B., Baglio, S. R., Philippar, U., Pillarisetti, K., et al. (2026) · HemaSphere · doi:10.1002/hem3.70487
Ataxia and Balance Disorders Associated with GPRC5D-Directed Therapies in Relapsed/Refractory Multiple Myeloma: A Case Series with Practical Recommendations for Management
Byun, J. M., Hungria, V., van de Donk, N. W. C. J., Searle, E. J., Bal, S., Ye, J. C., Mateos, M.-V., Rodríguez‐Otero, P., Mailankody, S., Fu, W., et al. (2026) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2026.10.019

Authors: Smith, E. L., Harrington, K., Staehr, M., Masakayan, R., Jones, J., Long, T. J., Ng, K. Y., Ghoddusi, M., Purdon, T. J., Wang, X., Do, T., Pham, M. T., Brown, J. M., De Larrea, C. F., Olson, E., Peguero, E., Wang, P., Liu, H., Xu, Y., Garrett-Thomson, S. C., Almo, S. C., Wendel, H.-G., Riviere, I., Liu, C., Sather, B., & Brentjens, R. J.
Affiliations: Memorial Sloan Kettering Cancer Center (US)
Juno Therapeutics (United States) (US)
Cellular Therapeutics Center, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Sloan Kettering Institute, New York, NY 10065, USA.
Eureka Therapeutics (United States) (US)
Albert Einstein College of Medicine (US)
Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Eureka Therapeutics, Emeryville, CA 94608, USA.
Corresponding author: Brentjens, Renier J.
ORCID: Smith, Eric L.
Staehr, Mette
Masakayan, Reed
Jones, Jon
Ng, Khong Y.
Ghoddusi, Majid
Purdon, Terence J.
Wang, Xiuyan
Brown, Jessica M.
Peguero, Elizabeth
Garrett-Thomson, Sarah C.
Almo, Steven C.
Wendel, Hans-Guido
Sather, Blythe
Brentjens, Renier J.
Venue: Science Translational Medicine
Publisher: American Association for the Advancement of Science (AAAS)
Published: 2019-03-27
Volume: 11
Issue: 485
ISSN: 1946-6234 (ISSN-L)
1946-6242
DOI: 10.1126/scitranslmed.aau7746
PMC: PMC7508042
OpenAlex: W2923396001
Cited by: 391
References: 35
Citations by year: 2026: 31 · 2025: 55 · 2024: 79 · 2023: 68 · 2022: 46 · 2021: 55 · 2020: 42 · 2019: 14
FWCI: 16.36
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Science Translational Medicine (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health (R01 CA198095, R01 HG008325)
National Cancer Institute (P30 CA008748, U54 OD020355-01, PO1 CA190174-01, P01 CA059350, P30 CA013330, R01 CA138738-05)
Multiple Myeloma Research Foundation
American Society of Hematology
Leukemia and Lymphoma Society
Topics: Health Sciences › Medicine › Oncology › CAR-T cell therapy research
Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
Keywords: GPRC5D, multiple myeloma, CAR T-cell therapy, BCMA, scFv, phage display
MeSH terms: Receptors, Chimeric Antigen, Animals, Antibody Specificity, Humans, Multiple Myeloma, RNA, Messenger, Gene Expression, Immunotherapy, Adoptive, Mice, SCID, Mice, Inbred NOD, Xenograft Model Antitumor Assays, Receptors, G-Protein-Coupled, Cell Line, Tumor, Mice, B-Cell Maturation Antigen, Single-Chain Antibodies, Translational Research, Biomedical

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks